Summit Therapeutics (SMMT) Enterprise Value (2016 - 2026)
Summit Therapeutics filings provide 13 years of Enterprise Value readings, the most recent being -$106.8 million for Q1 2026.
- Quarterly Enterprise Value rose 49.57% to -$106.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$106.8 million through Mar 2026, up 49.57% year-over-year, with the annual reading at -$225.6 million for FY2025, 45.29% up from the prior year.
- Enterprise Value hit -$106.8 million in Q1 2026 for Summit Therapeutics, up from -$225.6 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$23.8 million in Q3 2023 and bottomed at -$648.6 million in Q4 2022.
- Average Enterprise Value over 5 years is -$200.0 million, with a median of -$211.8 million recorded in 2025.
- The largest annual shift saw Enterprise Value surged 88.99% in 2023 before it plummeted 935.93% in 2025.
- Summit Therapeutics' Enterprise Value stood at -$648.6 million in 2022, then surged by 88.99% to -$71.4 million in 2023, then crashed by 477.32% to -$412.3 million in 2024, then surged by 45.29% to -$225.6 million in 2025, then soared by 52.64% to -$106.8 million in 2026.
- Per Business Quant, the three most recent readings for SMMT's Enterprise Value are -$106.8 million (Q1 2026), -$225.6 million (Q4 2025), and -$238.9 million (Q3 2025).